People

Research assistant at Biocross, a developer of blood-based biomarker assays for neurodegenerative diseases.

Ingrid Kelly, also published as Ingrid Kelly Spillmann, is a XISTA Science Ventures partner and Brightmind.AI adviser on intellectual property. She has doctoral training in molecular biology at Cambridge and professional experience in patent law, corporate IP and technology transfer. XISTA’s own biography links the full-name identity and expressly names Brightmind.AI among companies she supports.

Walter Greenleaf is a behavioral neuroscientist and medical-technology developer whose Stanford Virtual Human Interaction Lab biography describes research in virtual reality, digital health and clinical applications. His work includes Stanford longevity research and medical product development. BehaVR named him on its scientific advisory board in October 2021. The affiliation is historical and does not establish a current term or investment.

Published in Orbit’s combined Venture Partners and Experts in Residence section; the site also lists Chief Strategy Officer, DDB Chicago. The section does not distinguish individual venture partner versus expert status unless stated explicitly.

Compliance analyst and office manager at ACT Venture Capital since January 2022. Supports the investment team and limited partner reporting and previously worked at AIB; a qualified financial advisor.

Works in accounts at ACT Venture Capital. Joined in 2017 and manages accounting and financial operations for the management company.

Fund accountant at ACT Venture Capital. Joined its financial control department in 2003 and works on operations across multiple funds.

Financial controller at ACT Venture Capital. Joined its financial control department in 1994 and became controller in 1996, overseeing group reporting, tax and regulatory compliance.

Associate at ACT Venture Capital with investment experience at Enterprise Ireland and ISIF and transaction services experience at Deloitte. A chartered accountant with degrees from University College Cork and University College Dublin and a UCD diploma in artificial intelligence.

Principal at ACT Venture Capital and Kauffman Fellow who sources investments, leads diligence and supports portfolio strategy. Previously founded retail and marketing technology businesses; studied history and politics at UCD and executive finance and venture capital programs.

Principal at ACT Venture Capital responsible for sourcing investments, diligence and portfolio support. Previously worked in Paddy Power Betfair corporate development and financial services; a CFA charterholder and Trinity College Dublin business and economics graduate.

General partner at ACT Venture Capital with prior software operating and business development roles at Misys, Kindle Banking Systems and Kao Infosystems, and experience at Enterprise Ireland. Studied commerce at University College Cork.

Managing partner at ACT Venture Capital, which he joined in 1996 after software engineering and business development roles at EDS. Holds physics and mathematics qualifications from UCD and an MBA from Trinity College Dublin; formerly chaired the Irish Venture Capital Association.

Technology investor and general partner at ACT Venture Capital. Previously worked in KPMG corporate finance; holds a law degree from University College Dublin and is a fellow of Chartered Accountants Ireland.

M. Lance Patton is president of Topcon Healthcare, Inc., effective April 1, 2026. Previously chief commercial officer, appointed in 2024. Published background includes ophthalmic medical-device and diagnostic commercialization. October 6, 2026 issuer announcement reconfirms president; his existing RetiSpec board role is separate.

Robert N. Weinreb, MD, chairs the Scientific Advisory Board of Amydis. His clinical and scientific work focuses on glaucoma, optic neuropathy, retinal imaging and neuroprotection; he trained at Harvard Medical School and UC San Francisco. Robert N. Weinreb advises Spinogenix on science. His clinical and research work at UC San Diego encompasses ophthalmology, glaucoma, retinal imaging and neuroprotection, alongside existing Amydis and RetiSpec affiliations. Robert N. Weinreb is named a machineMD board member in its current public directory. This matches the UC San Diego ophthalmologist and glaucoma researcher already advising Amydis and Spinogenix; prior portrait and all existing roles preserved. Robert N. Weinreb is a current Iantrek board member and glaucoma clinician/researcher at the Shiley Eye Institute. His prior neurological and ophthalmic scientific affiliations and authentic portrait are preserved.

Tyler Shultz is publicly listed by Fusion Fund as Fusion Expert Network Member (network affiliation). His background includes diagnostics entrepreneurship and ethical innovation. A Stanford-trained biologist and Theranos whistleblower, he co-founded two diagnostic companies. Verge HealthTech Fund’s own sources independently confirm his venture-partner affiliation. Outside affiliations are included as published career context, not independently asserted new employment appointments.

Physician and public-health specialist listed in HCC’s external advisory network. The published biography describes Singapore healthcare policy, consulting and system-transformation experience; his existing Verge HealthTech Fund adviser identity is preserved.

Leads discovery and environmental sciences studies, including ADME, dermal absorption, pharmacokinetics and endocrine disruption. Earned a doctorate in biomedical research at the University of Amsterdam.

Virologist responsible for the scientific portfolio of Charles River’s biologics testing solutions. Has over thirty years of experience in virus safety testing and virus and prion clearance.

Toxicologist with a master’s degree and preclinical research experience, working on digital innovation and alternatives to animal testing for drug safety assessment.

Toxicologist specializing in lung pharmacology, inhalation risk assessment and organotypic cultures. Earned a doctorate in human lung development at Southampton and an MBA at the Open University.

Miia Kivipelto is a scientific adviser to NeuroVision Imaging’s BrainHealth programme. Dr. Kivipelto is Director of Research, Development, Education and Innovation at Karolinska Institute, in addition to a Karolinska University Hospital Professor. She is also a leader of the Finnish Geriatric Intervention Study to Prevent Cognitive Impairment and Disability (FINGERS) trial, which studies lifestyle intervention for Alzheimer’s disease. Miia Kivipelto is listed on the Alzheimer’s Drug Discovery Foundation’s Board of Governors in its Governors group. The foundation lists the outside professional affiliation: Professor of Clinical Geriatrics, Karolinska Institutet Center for Alzheimer Research; Senior Geriatrician and Director for Research and Development of Medical Unit Aging, Karolinska University Hospital. This is a foundation governance or honorary affiliation, not an assertion of operating employment.

Joined the Charles River board in October 2019. Former chief financial officer of TIAA with prior finance roles at Wyndham, Cendant, MetLife and Transamerica.

Cancer researcher and former CEO of Memorial Sloan Kettering Cancer Center, serving from 2010 to 2022. Co-founded Agios Pharmaceuticals and joined the Charles River board in December 2022.

Joined the Charles River board in July 2017. Co-founded Rallybio and held research and development leadership roles at Alexion, AstraZeneca and Pfizer.

Former chief information officer at Alexion Pharmaceuticals and a member of the Charles River board.

Joined the Charles River board in January 2024. Has commercial pharmaceutical leadership experience at Novartis and Johnson & Johnson.

Joined the Charles River board in May 2025. Has lithium industry leadership experience at Livent and Arcadium and finance experience at FMC and Goldman Sachs.

Joined Charles River in 1976 and served as CEO from 1992 until retirement in May 2026. Remains a nonexecutive director.

Joined the Charles River board in May 2025. Has biotechnology leadership experience at Rapport Therapeutics, Cerevel and Tiburio.

Joined the Charles River board in May 2025. Has investment engagement and capital markets experience at Elliott and Goldman Sachs.

Physician and scientist who previously served as dean of Duke University School of Medicine. Her research concerns iron metabolism.

Joined Charles River in 2019 after approximately twenty years at IBM. Leads people operations and total rewards.

Joined Charles River in 2017. Previously held finance roles at Bruker and was an Ernst & Young partner.

Joined Charles River in 2000 and became chief commercial officer in 2024. Holds an executive MBA from Suffolk University.

Joined Charles River in 2008. Trained in veterinary medicine at Glasgow and virology at Louis Pasteur University.

Joined Charles River in 2001 in Germany. Leads global manufacturing, including biologics and contract development and manufacturing operations.

Joined Charles River in 2026. Previously held legal leadership positions at Alcon and worked at Sanofi and international law firms.

Joined Charles River as a study director in 2004 and became senior vice president in 2025. Previously worked in FBI microbiology.

Joined Charles River in 2007 and became chief communications officer in 2020. Holds a journalism degree from Northeastern University.

Joined Charles River in 2026 and chairs its scientific advisory board. Previously served as FDA chief scientist and principal deputy commissioner and chaired pharmacology at Johns Hopkins.

Joined Charles River through its 2004 merger with Inveresk. Leads European safety assessment operations.

Joined Charles River in 2000 and became executive vice president in 2022. Leads global discovery and safety assessment.

Joined Charles River in 2021. Previously worked at McKinsey, DoubleClick and Accenture.

Joined Charles River in 2005 and moved into corporate development in 2014. Oversees corporate development and strategy.

Joined Charles River in 2019 and leads its people organization. Previously worked at ITT and IBM.

Joined Charles River in April 2026. Previously held finance leadership roles at Premier, Dentsply Sirona and Integra.

Joined Charles River in 1989 and became CEO in May 2026 after serving as chief operating officer.

Iya Khalil is a physicist and AI entrepreneur who co-founded GNS Healthcare, now Aitia, with Colin Hill in 2000. She previously served as its chief commercial officer and executive vice president. She earned a physics doctorate at Cornell University. Her later work includes pharmaceutical AI and genome-science leadership; her founder role does not imply a current Aitia executive appointment.

Timothy Thompson is an independent director at Aitia. He previously led Aptus Health, Intervention Insights and Proventys and held business-development leadership roles at Aetna and PHT. He founded Clinical Data Solutions and studied zoology and biochemistry at the University of New Hampshire.

Peter Neupert serves on Aitia’s board, bringing experience in technology, healthcare and corporate governance. He previously held leadership positions at Microsoft and was the founding chief executive of Drugstore.com. He studied at Colorado College and Dartmouth’s Tuck School of Business. Labcorp public biography: Peter M. Neupert Director Peter M. Neupert has served as a director of the Company since January 1, 2013 and previously served as the Board’s lead independent director from July 2019 until June 2023. Mr. Neupert was an Operating Partner at Health Evolution Partners, a health only, middle market private equity firm, from January 2012 until June 2015. Prior to that, Mr. Neupert served as Corporate Vice President of the Microsoft Health Solutions Group from its formation in 2005 to January 2012. Mr. Neupert served on the President George W. Bush’s Information Technology Advisory Committee (PITAC), co-chairing the Health Information Technology Subcommittee and helping to drive the “Revolutionizing Health Care Through Information Technology” report, published in June 2004. Mr. Neupert served as the founding President and Chief Executive Officer of drugstore.com from 1998 to 2001 and as Chairman of the board of directors through September 2004. Mr. Neupert has served as a director of Fortrea Holdings, Inc. since it became publicly traded in June 2023. Mr. Neupert has served as a director of Adaptive Biotechnologies Corporation since December 2013 and currently serves as the Lead Independent Director. He served on the Board of Directors of Quality Systems, Inc., now known as NextGen Healthcare, Inc., from August 2013 to January 2014. He previously served as a trustee for the Fred Hutchinson Cancer Research Center and was an active member of the Institute of Medicine’s Roundtable on Value & Science-Driven Healthcare from 2007 to 2011. Mr. Neupert is an audit committee financial expert as a result of his experience, including his experience as CEO and Chairman of drugstore.com.

David W. Miller is an Aitia board observer and a GHO Capital operating partner with pharmaceutical market-access and health-economics experience. He previously held leadership roles at Biogen, Elan and GlaxoSmithKline. He trained in pharmacy at the University of Iowa and earned a doctorate at the University of Maryland Baltimore.

Joel Krikston is an Aitia board observer and a venture-investment executive at Merck Global Health Innovation Fund. His prior experience includes Johnson & Johnson Development Corporation and healthcare investment banking. He studied finance at Fairfield University and earned an MBA at NYU Stern.

Josh Holden serves on Aitia’s board and co-founded Capital Pulse, a medical-claims valuation and financing business. His prior experience includes OpenDoor, Fina Technologies and trading roles at Goldman Sachs, Deutsche Bank and Countrywide. He holds engineering degrees from MIT.

Craig Cimini is a board observer at Aitia and leads corporate venture investment strategy for The Cigna Group Ventures. His work covers minority investments, partnerships and joint ventures. He studied at Gettysburg College and Cornell University.

Hairong Zhang joined Aitia in 2023 and leads corporate strategy, development and strategic data partnerships. She previously worked in medical-device regulatory affairs and commercial strategy. She holds biomedical engineering and business graduate degrees from Cornell University.

Jerome Windsor leads business development and strategic alliances at Aitia. His experience spans biopharma, payers and digital health, with previous roles at Celata Bioinnovations, Median Technologies, UnitedHealth Group’s i3, Accenture, PwC and GSK. He trained in pharmacy and business.

Joshua Thompson leads Aitia’s software engineering and language-model integration work, including the REFS platform and tools for interpreting causal models. He joined Aitia in 2018 after studying mathematics and computer science at Texas A&M University–Corpus Christi.

Fintan Steele joined Aitia in 2026 to lead scientific and corporate communications. His prior positions include communications leadership at SomaLogic, the Broad Institute and Novartis Institutes for BioMedical Research, as well as scientific publishing. He earned a doctorate in biological sciences at Notre Dame.

So-Youn Shin leads a neuroscience team at Aitia focused on identifying therapies for neurodegenerative diseases. She previously conducted research at the Wellcome Trust Sanger Institute and University of Bristol. She studied at Seoul National University and earned graduate degrees in applied mathematics and statistics at Stony Brook University.

Brenton Paolella joined Aitia in 2026 to lead precision oncology teams and preclinical and clinical programs. He previously led cancer genomics target discovery at Merck Research Labs and worked on the Broad Institute’s Cancer Dependency Map. He earned a doctorate at Dartmouth’s Geisel School of Medicine.

Lyudmila Makowsky leads finance at Aitia. Her previous finance leadership roles include Sensata Technologies, Philips, SGS Life Sciences, Labcorp and Covance, with experience in strategic planning, financial analysis, business integration and governance.

Jeanne Latourelle leads precision medicine at Aitia. Before joining in 2015, she conducted genetic epidemiology research at Boston University, including neurodegenerative disease research. She holds degrees in biomedical engineering, mechanical engineering and epidemiology from Boston University and MIT.

Colin Hill is Aitia’s co-founder and chief executive officer, leading its causal AI and digital-twin drug discovery business. He studied physics at Virginia Tech, McGill and Cornell. His experience includes biotechnology and healthcare board service and developing AI applications for precision medicine.

Jean-Michel Gries is president and chief operating officer of Aitia. His previous leadership positions span Hengenix, Henlius, Kodikaz Therapeutics, Roche, Alcon, Covance and Parexel. His expertise includes clinical pharmacology, translational medicine, drug development and licensing.

Tom Grammatopoulos leads business development and strategy at Aitia, drawing on neuroscience, mitochondrial biology and drug-discovery experience. He previously held leadership roles at iNeuro Therapeutics, Lucy Therapeutics and Charles River Laboratories, and co-founded BioEnergetics. He earned a doctorate in cell and structural biology at the University of Illinois Urbana-Champaign.

Bruce Church develops the REFS algorithms and leads research and technology development at Aitia. A member of its founding team, he previously researched protein-folding optimization at Cornell University, where he earned degrees in engineering physics and applied physics.

George Scangos is an Octave Bioscience board director and former CEO of Vir Biotechnology, Biogen and Exelixis. His background includes biotechnology research and management.

Lucy Coassin is an Octave Bioscience board director and a Northpond Ventures investor. Her earlier commercial experience includes Current Health, Science 37, Genentech and Life Technologies. Northpond’s current team lists Lucy Coassin as Director.

Grant Heidrich III is an Octave Bioscience board director. He previously co-led Mayfield’s healthcare investing and served in venture-industry leadership organizations.

Tom Hawes is an Octave Bioscience board director and a healthcare investor associated with Sandbox Industries and the BlueCross BlueShield fund-management team.

Brook Byers is an Octave Bioscience board director and a founding member of Kleiner Perkins. His venture investing career includes building biotechnology and healthcare companies.

William Hagstrom founded Octave Bioscience and serves as its board chair, following his earlier tenure as CEO. His prior leadership experience includes Crescendo Bioscience and Urocor.

Darin Okuda is a senior medical advisor to Octave Bioscience and a UT Southwestern neurology professor. He researches multiple sclerosis, neuroimaging and radiologically isolated syndrome.

Jennifer Graves is a consultant senior medical director at Octave Bioscience and a UC San Diego neurosciences professor. Her research covers multiple sclerosis, biomarkers and wearable assessment.

Erika B. Ortiz directs people operations at Octave Bioscience. Her previous HR leadership roles include Simple Things, Rivian, Nauto and Essential Products.

Jennifer Mellum leads marketing at Octave Bioscience. Her earlier marketing and customer-experience roles include GRAIL, GeneDx, Prime Therapeutics, Risk Management Solutions and Clorox.

Zachary Fernandes leads business development at Octave Bioscience. He previously led diagnostics partnerships at Quanterix and held business development roles at Veritas Genetics and Mission Bio.

David Brazel leads data science at Octave Bioscience, supporting its MSDA platform and biomarker development. He previously worked at Color Health and Sandia National Laboratories.

Terrie Livingston leads medical affairs at Octave Bioscience. Her pharmaceutical and clinical research background includes Pharmacia, Novartis, Biogen and EMD Serono.

Kirk Stockwood leads Octave Bioscience’s commercial activities. His diagnostics and life-sciences experience includes Quanterix, 10x Genomics, Natera and Color Health.